Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
Completed · Phase 2
Conditions studied: BRAF V600E-mutant Metastatic Colorectal Cancer
In brief
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.
Key facts
- Study ID
- NCT03693170
- Run by
- Pierre Fabre Medicament
- People needed
- 95
- Starts
- 2019-01-17
- Expected to finish
- 2023-04-27
- Last updated by the study team
- 2026-07-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female ≥ 18 years of age
- Histologically or cytologically confirmed CRC that is metastatic
- Presence of BRAF V600E in tumor tissue determined by local assay at any time prior to screening
- Evidence of measurable disease as per RECIST, v1.1
- Subject able to receive cetuximab as per approved label with regards to RAS status
- Eastern Cooperative Oncology Group Status (ECOG) 0 or 1
- Adequate renal, hepatic, cardiac and bone marrow functions and adequate electrolytes as per protocol
- Subject able to take oral medications
You may not qualify if…
- Prior systemic therapy for metastatic disease
- Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab or other anti-EGFR inhibitors
- Symptomatic brain metastasis or Leptomeningeal disease
- History or current evidence of Retinal Vein Occlusion (RVO) or current risk factors for RVO
- History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to first dose.
- Impaired cardiovascular function or clinically significant cardiovascular diseases: history of myocardial infarction or coronary disorders within 6 months prior to start of study treatment, symptomatic congestive heart failure (grade 2 or higher), past or current clinically significant arrhythmia and/or conduction disorder within 6 months prior to study treatment start
- History of thromboembolic or cerebrovascular events within 6 months prior to start of study treatment
- Concurrent neuromuscular disorder that is associated with potential elevation of Creatine Kinase
- Known contraindication to cetuximab administration as per SPC/approved label
Where it is running
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- PC dba West Cancer Center — Germantown, Tennessee, United States
- Krankenhaus der Barmherzigen Brüder — Vienna, Austria
- UZ Gent, Gastro-Enterology — Ghent, East Flanders, Belgium
- Trial DIO, UZ Gasthuisberg — Leuven, Flemish Brabant, Belgium
- Cliniques universitaires Saint-Luc — Brussels, Belgium
- ICM- VAL d 'Aurelle — Montpellier, Cedex 5, France
- Hôpital Morvan CHRU de Brest Institut de cancérologie et d'hematologie — Brest, France
- AP-HM CHU Timone — Marseille, France
- Hôpital Cochin Gastroenterology — Paris, France
- Hôpital Europeen Georges Pompidou — Paris, France
- Hôpital Saint Antoine — Paris, France
- HOPITAL HAUT-LEVEQUE, Av de MAGELLAN — Pessac, France
- ICO- Site René Gauducheau — Saint-Herblain, France
- CHU TOULOUSE Rangueil — Toulouse, France
- IRCCS Ospedale Casa Sollievo della Sofferenza — San Giovanni Rotondo, Foggia, Italy
- Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori — Meldola, Forlì-Cesena, Italy
- Fondazione del Piemonte per l'Oncologia IRCC Candiolo — Candiolo, Italy
- Ospedale Policlinic San Martin — Genova, Italy
- Ospedale S.M. Misericordia — Perugia, Italy
- Pierre Fabre Investigative Site — Nagoya, Aichi-ken, Japan
- Pierre Fabre Investigative Site — Kashiwa, Chiba, Japan
- Pierre Fabre Investigative Site — Fukuoka, Fukuoka, Japan
- Pierre Fabre Investigative Site — Osaka, Osaka, Japan
- Pierre Fabre Investigative Site — Nagaizumi-cho, Shizuoka, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.